Mental Health Research Institute of Victoria and Monash University, Victoria, Australia
Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
Correspondence: Professor Nicholas A. Keks, Delmont Hospital, 298 Warrigal Road, Glen Iris, VIC 3146, Australia. Email: Nicholas.keks{at}med.monash.edu.au
Declaration of interest N. K. has received support from or been a consultant for AstraZeneca, Bristol-Meyers Squibb, Janssen Pharmaceutica, Eli Lilly, Sanofi-Synthelabo, Pfizer and Wyeth. M.I., A.K. and K.K. are employees of Johnson & Johnson.
Background The efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic.
Aims To compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder.
Method Patients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day).
Results In the 13-week phase, long-acting risperidone was at least as effective as (not inferior to) oral olanzapine. In the 12-month phase, significant improvements in the Positive and Negative Syndrome Scale (PANSS) total and factor scores from baseline to month 12 and end-point were seen in both groups of patients. Few patients discontinued treatment because of an adverse event.
Conclusions Both treatments were efficacious and well tolerated.
Related articles in BJP:
This article has been cited by other articles:
![]() |
D. Taylor Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review The British Journal of Psychiatry, November 1, 2009; 195(52): S13 - S19. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Haddad, M. Taylor, and O. S. Niaz First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies The British Journal of Psychiatry, November 1, 2009; 195(52): S20 - S28. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Fleischhacker Second-generation antipsychotic long-acting injections: systematic review The British Journal of Psychiatry, November 1, 2009; 195(52): S29 - S36. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tyrer From the Editor's desk The British Journal of Psychiatry, December 1, 2008; 193(6): 524 - 524. [Full Text] [PDF] |
||||
Read all eLetters